Female-selective mechanisms promoting migraine.
Calcitonin gene related peptide
Gepants
Migraine
Nociceptor
Pain
Prolactin
Sexual dimorphism
Journal
The journal of headache and pain
ISSN: 1129-2377
Titre abrégé: J Headache Pain
Pays: England
ID NLM: 100940562
Informations de publication
Date de publication:
24 Apr 2024
24 Apr 2024
Historique:
received:
03
04
2024
accepted:
15
04
2024
medline:
25
4
2024
pubmed:
25
4
2024
entrez:
24
4
2024
Statut:
epublish
Résumé
Sexual dimorphism has been revealed for many neurological disorders including chronic pain. Prelicinal studies and post-mortem analyses from male and female human donors reveal sexual dimorphism of nociceptors at transcript, protein and functional levels suggesting different mechanisms that may promote pain in men and women. Migraine is a common female-prevalent neurological disorder that is characterized by painful and debilitating headache. Prolactin is a neurohormone that circulates at higher levels in females and that has been implicated clinically in migraine. Prolactin sensitizes sensory neurons from female mice, non-human primates and humans revealing a female-selective pain mechanism that is conserved evolutionarily and likely translationally relevant. Prolactin produces female-selective migraine-like pain behaviors in rodents and enhances the release of calcitonin gene-related peptide (CGRP), a neurotransmitter that is causal in promoting migraine in many patients. CGRP, like prolactin, produces female-selective migraine-like pain behaviors. Consistent with these observations, publicly available clinical data indicate that small molecule CGRP-receptor antagonists are preferentially effective in treatment of acute migraine therapy in women. Collectively, these observations support the conclusion of qualitative sex differences promoting migraine pain providing the opportunity to tailor therapies based on patient sex for improved outcomes. Additionally, patient sex should be considered in design of clinical trials for migraine as well as for pain and reassessment of past trials may be warranted.
Identifiants
pubmed: 38658853
doi: 10.1186/s10194-024-01771-w
pii: 10.1186/s10194-024-01771-w
doi:
Substances chimiques
Calcitonin Gene-Related Peptide
JHB2QIZ69Z
Prolactin
9002-62-4
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
63Subventions
Organisme : National Institute for Health Care Management Foundation
ID : R01NS1295
Organisme : National Institute for Health Care Management Foundation
ID : R01NS1295
Informations de copyright
© 2024. The Author(s).
Références
Canavan C, West J, Card T (2014) The epidemiology of irritable bowel syndrome. Clin Epidemiol 6:71–80. https://doi.org/10.2147/CLEP.S40245
doi: 10.2147/CLEP.S40245
pubmed: 24523597
pmcid: 3921083
Mogil JS (2012) Sex differences in pain and pain inhibition: multiple explanations of a controversial phenomenon. Nat Rev Neurosci 13(12):859–866. https://doi.org/10.1038/nrn3360
doi: 10.1038/nrn3360
pubmed: 23165262
Mogil JS (2020) Qualitative sex differences in pain processing: emerging evidence of a biased literature. Nat Rev Neurosci 21(7):353–365. https://doi.org/10.1038/s41583-020-0310-6
doi: 10.1038/s41583-020-0310-6
pubmed: 32440016
Ruau D, Liu LY, Clark JD, Angst MS, Butte AJ (2012) Sex differences in reported pain across 11,000 patients captured in electronic medical records. J Pain 13(3):228–234. https://doi.org/10.1016/j.jpain.2011.11.002
doi: 10.1016/j.jpain.2011.11.002
pubmed: 22245360
pmcid: 3293998
Steingrimsdottir OA, Landmark T, Macfarlane GJ, Nielsen CS (2017) Defining chronic pain in epidemiological studies: a systematic review and meta-analysis. Pain 158(11):2092–2107. https://doi.org/10.1097/j.pain.0000000000001009
doi: 10.1097/j.pain.0000000000001009
pubmed: 28767506
Bartley EJ, Fillingim RB (2013) Sex differences in pain: a brief review of clinical and experimental findings. Br J Anaesth 111(1):52–58. https://doi.org/10.1093/bja/aet127
doi: 10.1093/bja/aet127
pubmed: 23794645
pmcid: 3690315
Porreca F, Navratilova E, Hirman J, van den Brink AM, Lipton RB, Dodick DW (2024) Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia 44(3):3331024241238153. https://doi.org/10.1177/03331024241238153
doi: 10.1177/03331024241238153
pubmed: 38477313
Porreca FN, Navratilova E, Hirman J, MaassenVanDenBrink A, Lipton RB, Dodick DW (2023) Translational impact of basic science promotes a new era of precision medicine for migraine. MedRxIV (preprint)
Diseases GBD, Injuries C (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of Disease Study 2019. Lancet 396(10258):1204–1222. https://doi.org/10.1016/S0140-6736(20)30925-9
doi: 10.1016/S0140-6736(20)30925-9
Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) Lifting the Burden: the global campaign against H. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21(1):137. https://doi.org/10.1186/s10194-020-01208-0
doi: 10.1186/s10194-020-01208-0
pubmed: 33267788
pmcid: 7708887
Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A et al (2007) The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27(3):193–210. https://doi.org/10.1111/j.1468-2982.2007.01288.x
doi: 10.1111/j.1468-2982.2007.01288.x
pubmed: 17381554
Ahmad SR, Rosendale N, Sex, Gender Considerations in Episodic Migraine (2022) Curr Pain Headache Rep 26(7):505–516. https://doi.org/10.1007/s11916-022-01052-8
doi: 10.1007/s11916-022-01052-8
pubmed: 35679008
pmcid: 9325838
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68(5):343–349. https://doi.org/10.1212/01.wnl.0000252808.97649.21
doi: 10.1212/01.wnl.0000252808.97649.21
pubmed: 17261680
Buse DC, Loder EW, Gorman JA, Stewart WF, Reed ML, Fanning KM et al (2013) Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache 53(8):1278–1299. https://doi.org/10.1111/head.12150
doi: 10.1111/head.12150
pubmed: 23808666
Brennan KC, Pietrobon D, A Systems Neuroscience Approach to Migraine (2018) Neuron 97(5):1004–1021. https://doi.org/10.1016/j.neuron.2018.01.029
doi: 10.1016/j.neuron.2018.01.029
pubmed: 29518355
pmcid: 6402597
Dodick DW (2018) A phase-by-phase review of Migraine Pathophysiology. Headache 58 Suppl 14–16. https://doi.org/10.1111/head.13300
Olesen J (2018) International classification of Headache disorders. Lancet Neurol 17(5):396–397. https://doi.org/10.1016/S1474-4422(18)30085-1
doi: 10.1016/S1474-4422(18)30085-1
pubmed: 29550365
Close LN, Eftekhari S, Wang M, Charles AC, Russo AF (2019) Cortical spreading depression as a site of origin for migraine: role of CGRP. Cephalalgia 39(3):428–434. https://doi.org/10.1177/0333102418774299
doi: 10.1177/0333102418774299
pubmed: 29695168
Lemale CL, Luckl J, Horst V, Reiffurth C, Major S, Hecht N et al (2022) Migraine aura, transient ischemic attacks, stroke, and dying of the Brain share the same key pathophysiological process in neurons driven by Gibbs-Donnan Forces, namely spreading depolarization. Front Cell Neurosci 16:837650. https://doi.org/10.3389/fncel.2022.837650
doi: 10.3389/fncel.2022.837650
pubmed: 35237133
pmcid: 8884062
Vinogradova LV (2018) Initiation of spreading depression by synaptic and network hyperactivity: insights into trigger mechanisms of migraine aura. Cephalalgia 38(6):1177–1187. https://doi.org/10.1177/0333102417724151
doi: 10.1177/0333102417724151
pubmed: 28750590
Buse DC, Rupnow MF, Lipton RB (2009) Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 84(5):422–435. https://doi.org/10.1016/S0025-6196(11)60561-2
doi: 10.1016/S0025-6196(11)60561-2
pubmed: 19411439
pmcid: 2676125
Dahlof CG, Dimenas E (1995) Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia 15(1):31–36. https://doi.org/10.1046/j.1468-2982.1995.1501031.x
doi: 10.1046/j.1468-2982.1995.1501031.x
pubmed: 7758095
Dueland AN, Leira R, Cabelli ST (2005) The impact of migraine on psychological well-being of young women and their communication with physicians about migraine: a multinational study. Curr Med Res Opin 21(8):1297–1305. https://doi.org/10.1185/030079905X56394
doi: 10.1185/030079905X56394
pubmed: 16083540
Linde M, Dahlof C (2004) Attitudes and burden of disease among self-considered migraineurs–a nation-wide population-based survey in Sweden. Cephalalgia 24(6):455–465. https://doi.org/10.1111/j.1468-2982.2004.00703.x
doi: 10.1111/j.1468-2982.2004.00703.x
pubmed: 15154855
Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML (1999) Burden of migraine in the United States: disability and economic costs. Arch Intern Med 159(8):813–818. https://doi.org/10.1001/archinte.159.8.813
doi: 10.1001/archinte.159.8.813
pubmed: 10219926
Seddik AH, Branner JC, Ostwald DA, Schramm SH, Bierbaum M, Katsarava Z (2020) The socioeconomic burden of migraine: an evaluation of productivity losses due to migraine headaches based on a population study in Germany. Cephalalgia 40(14):1551–1560. https://doi.org/10.1177/0333102420944842
doi: 10.1177/0333102420944842
pubmed: 32762249
Stewart WF, Lipton RB (1994) The economic and social impact of migraine. Eur Neurol 34 Suppl 2:12 – 7. https://doi.org/10.1159/000119527
Karsan N, Goadsby PJ (2022) New oral drugs for Migraine. CNS Drugs 36(9):933–949. https://doi.org/10.1007/s40263-022-00948-8
doi: 10.1007/s40263-022-00948-8
pubmed: 36031682
pmcid: 9477894
Lee MJ, Al-Karagholi MA, Reuter U (2023) New migraine prophylactic drugs: current evidence and practical suggestions for non-responders to prior therapy. Cephalalgia 43(2):3331024221146315. https://doi.org/10.1177/03331024221146315
doi: 10.1177/03331024221146315
pubmed: 36759320
Puledda F, Silva EM, Suwanlaong K, Goadsby PJ (2023) Migraine: from pathophysiology to treatment. J Neurol 270(7):3654–3666. https://doi.org/10.1007/s00415-023-11706-1
doi: 10.1007/s00415-023-11706-1
pubmed: 37029836
pmcid: 10267278
Al-Hassany L, Goadsby PJ, Danser AHJ, MaassenVanDenBrink A (2022) Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol 21(3):284–294. https://doi.org/10.1016/S1474-4422(21)00409-9
doi: 10.1016/S1474-4422(21)00409-9
pubmed: 35093196
de Vries Lentsch S, Rubio-Beltran E, MaassenVanDenBrink A (2021) Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman’s life: implications for the efficacy and safety of novel antimigraine medications. Maturitas 145:73–77. https://doi.org/10.1016/j.maturitas.2020.12.012
doi: 10.1016/j.maturitas.2020.12.012
pubmed: 33541566
van Casteren DS, Kurth T, Danser AHJ, Terwindt GM, MaassenVanDenBrink A (2021) Sex differences in response to triptans: a systematic review and Meta-analysis. Neurology 96(4):162–170. https://doi.org/10.1212/WNL.0000000000011216
doi: 10.1212/WNL.0000000000011216
pubmed: 33208542
Szewczyk AK, Ulutas S, Akturk T, Al-Hassany L, Borner C, Cernigliaro F et al (2023) Prolactin and oxytocin: potential targets for migraine treatment. J Headache Pain 24(1):31. https://doi.org/10.1186/s10194-023-01557-6
doi: 10.1186/s10194-023-01557-6
pubmed: 36967387
pmcid: 10041814
Stewart WF, Wood C, Reed ML, Roy J, Lipton RB, Group AA (2008) Cumulative lifetime migraine incidence in women and men. Cephalalgia 28(11):1170–1178. https://doi.org/10.1111/j.1468-2982.2008.01666.x
doi: 10.1111/j.1468-2982.2008.01666.x
pubmed: 18644028
Pavlovic JM, Allshouse AA, Santoro NF, Crawford SL, Thurston RC, Neal-Perry GS et al (2016) Sex hormones in women with and without migraine: evidence of migraine-specific hormone profiles. Neurology 87(1):49–56. https://doi.org/10.1212/WNL.0000000000002798
doi: 10.1212/WNL.0000000000002798
pubmed: 27251885
pmcid: 4932235
MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A (2006) Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 67(12):2154–2158. https://doi.org/10.1212/01.wnl.0000233888.18228.19
doi: 10.1212/01.wnl.0000233888.18228.19
pubmed: 16971700
Bharadwaj VN, Porreca F, Cowan RP, Kori S, Silberstein SD, Yeomans DC (2021) A new hypothesis linking oxytocin to menstrual migraine. Headache 61(7):1051–1059. https://doi.org/10.1111/head.14152
doi: 10.1111/head.14152
pubmed: 34125955
Pavlovic JM, Buse DC, Sollars CM, Haut S, Lipton RB (2014) Trigger factors and premonitory features of migraine attacks: summary of studies. Headache 54(10):1670–1679. https://doi.org/10.1111/head.12468
doi: 10.1111/head.12468
pubmed: 25399858
Lyall M, de Oliveira BR, Mody SK (2023) Considerations for contraceptive use among patients with migraines. Curr Obstet Gynecol Rep. https://doi.org/10.1007/s13669-023-00349-8
doi: 10.1007/s13669-023-00349-8
van Lohuizen R, Paungarttner J, Lampl C, MaassenVanDenBrink A, Al-Hassany L (2023) Considerations for hormonal therapy in migraine patients: a critical review of current practice. Expert Rev Neurother 24(1):1–21. https://doi.org/10.1080/14737175.2023.2296610
doi: 10.1080/14737175.2023.2296610
pubmed: 38112066
Labastida-Ramirez A, Rubio-Beltran E, Villalon CM, MaassenVanDenBrink A (2019) Gender aspects of CGRP in migraine. Cephalalgia 39(3):435–444. https://doi.org/10.1177/0333102417739584
doi: 10.1177/0333102417739584
pubmed: 29082826
Raffaelli B, Storch E, Overeem LH, Terhart M, Fitzek MP, Lange KS et al (2023) Sex hormones and calcitonin gene-related peptide in women with migraine: a cross-sectional, matched Cohort Study. Neurology 100(17):e1825–e35. https://doi.org/10.1212/WNL.0000000000207114
doi: 10.1212/WNL.0000000000207114
pubmed: 36813730
pmcid: 10136010
Al-Karagholi MA, Kalatharan V, Ghanizada H, Dussor G, Ashina M (2023) Prolactin in headache and migraine: a systematic review of preclinical studies. Headache 63(5):577–584. https://doi.org/10.1111/head.14412
doi: 10.1111/head.14412
pubmed: 36752584
Al-Karagholi MA, Kalatharan V, Ghanizada H, Gram C, Dussor G, Ashina M (2023) Prolactin in headache and migraine: a systematic review of clinical studies. Cephalalgia 43(2):3331024221136286. https://doi.org/10.1177/03331024221136286
doi: 10.1177/03331024221136286
pubmed: 36718026
Avona A, Mason BN, Burgos-Vega C, Hovhannisyan AH, Belugin SN, Mecklenburg J et al (2021) Meningeal CGRP-Prolactin Interaction Evokes Female-Specific Migraine Behavior. Ann Neurol. 2021;89(6):1129-44. https://doi.org/10.1002/ana.26070
Watanabe M, Kopruszinski CM, Moutal A, Ikegami D, Khanna R, Chen Y et al (2022) Dysregulation of serum prolactin links the hypothalamus with female nociceptors to promote migraine. Brain 145(8):2894–2909. https://doi.org/10.1093/brain/awac104
doi: 10.1093/brain/awac104
pubmed: 35325034
pmcid: 9890468
Lipton RB, Buse DC, Hall CB, Tennen H, Defreitas TA, Borkowski TM et al (2014) Reduction in perceived stress as a migraine trigger: testing the let-down headache hypothesis. Neurology 82(16):1395–1401. https://doi.org/10.1212/WNL.0000000000000332
doi: 10.1212/WNL.0000000000000332
pubmed: 24670889
pmcid: 4001194
Oliveira MDC, Barea LM, Horn APK, Ongaratti BR, Soares JOD, Araujo B et al (2020) Resolution of headache after reduction of prolactin levels in hyperprolactinemic patients. Arq Neuropsiquiatr 78(1):28–33. https://doi.org/10.1590/0004-282X20190143
doi: 10.1590/0004-282X20190143
pubmed: 32074187
Avona A, Burgos-Vega C, Burton MD, Akopian AN, Price TJ, Dussor G (2019) Dural Calcitonin Gene-related peptide produces female-specific responses in Rodent Migraine models. J Neurosci 39(22):4323–4331. https://doi.org/10.1523/JNEUROSCI.0364-19.2019
doi: 10.1523/JNEUROSCI.0364-19.2019
pubmed: 30962278
pmcid: 6538861
Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I (1985) Calcitonin gene-related peptide is a potent vasodilator. Nature 313(5997):54–56. https://doi.org/10.1038/313054a0
doi: 10.1038/313054a0
pubmed: 3917554
Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L (2010) Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 169(2):683–696. https://doi.org/10.1016/j.neuroscience.2010.05.016
doi: 10.1016/j.neuroscience.2010.05.016
pubmed: 20472035
Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L (2013) Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain 14(11):1289–1303. https://doi.org/10.1016/j.jpain.2013.03.010
doi: 10.1016/j.jpain.2013.03.010
pubmed: 23958278
Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J (2002) CGRP may play a causative role in migraine. Cephalalgia 22(1):54–61. https://doi.org/10.1046/j.1468-2982.2002.00310.x
doi: 10.1046/j.1468-2982.2002.00310.x
pubmed: 11993614
Mulderry PK, Ghatei MA, Bishop AE, Allen YS, Polak JM, Bloom SR (1985) Distribution and chromatographic characterisation of CGRP-like immunoreactivity in the brain and gut of the rat. Regul Pept 12(2):133–143. https://doi.org/10.1016/0167-0115(85)90194-6
doi: 10.1016/0167-0115(85)90194-6
pubmed: 3877953
Russell FA, King R, Smillie SJ, Kodji X, Brain SD (2014) Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 94(4):1099–1142. https://doi.org/10.1152/physrev.00034.2013
doi: 10.1152/physrev.00034.2013
pubmed: 25287861
pmcid: 4187032
Garelja ML, Walker CS, Hay DL (2022) CGRP receptor antagonists for migraine. Are they also AMY(1) receptor antagonists? Br J Pharmacol 179(3):454–459. https://doi.org/10.1111/bph.15585
doi: 10.1111/bph.15585
pubmed: 34076887
Ji Y, Rizk A, Voulalas P, Aljohani H, Akerman S, Dussor G et al (2019) Sex differences in the expression of calcitonin gene-related peptide receptor components in the spinal trigeminal nucleus. Neurobiol Pain 6:100031. https://doi.org/10.1016/j.ynpai.2019.100031
doi: 10.1016/j.ynpai.2019.100031
pubmed: 31223141
pmcid: 6565752
Stucky NL, Gregory E, Winter MK, He YY, Hamilton ES, McCarson KE et al (2011) Sex differences in behavior and expression of CGRP-related genes in a rodent model of chronic migraine. Headache 51(5):674–692. https://doi.org/10.1111/j.1526-4610.2011.01882.x
doi: 10.1111/j.1526-4610.2011.01882.x
pubmed: 21521205
pmcid: 4079043
Diogenes A, Patwardhan AM, Jeske NA, Ruparel NB, Goffin V, Akopian AN et al (2006) Prolactin modulates TRPV1 in female rat trigeminal sensory neurons. J Neurosci 26(31):8126–8136. https://doi.org/10.1523/JNEUROSCI.0793-06.2006
doi: 10.1523/JNEUROSCI.0793-06.2006
pubmed: 16885226
pmcid: 6673790
Dubin AE, Patapoutian A (2010) Nociceptors: the sensors of the pain pathway. J Clin Invest 120(11):3760–3772. https://doi.org/10.1172/JCI42843
doi: 10.1172/JCI42843
pubmed: 21041958
pmcid: 2964977
Tavares-Ferreira D, Shiers S, Ray PR, Wangzhou A, Jeevakumar V, Sankaranarayanan I et al (2022) Spatial transcriptomics of dorsal root ganglia identifies molecular signatures of human nociceptors. Sci Transl Med 14(632):eabj8186. https://doi.org/10.1126/scitranslmed.abj8186
doi: 10.1126/scitranslmed.abj8186
pubmed: 35171654
pmcid: 9272153
Mecklenburg J, Zou Y, Wangzhou A, Garcia D, Lai Z, Tumanov AV et al (2020) Transcriptomic sex differences in sensory neuronal populations of mice. Sci Rep 10(1):15278. https://doi.org/10.1038/s41598-020-72285-z
doi: 10.1038/s41598-020-72285-z
pubmed: 32943709
pmcid: 7499251
Ray PR, Shiers S, Caruso JP, Tavares-Ferreira D, Sankaranarayanan I, Uhelski ML et al (2023) RNA profiling of human dorsal root ganglia reveals sex differences in mechanisms promoting neuropathic pain. Brain 146(2):749–766. https://doi.org/10.1093/brain/awac266
doi: 10.1093/brain/awac266
pubmed: 35867896
Stratton HDM, Dumaire N, Moutal A, ghetti A, Cotta T, Mitchell S, Yue X, Navratilova E, Porreca F (2023) Functional Sexual Dimorphism in Human Nociceptors. BioRxiv
Tavares-Ferreira D, Ray PR, Sankaranarayanan I, Mejia GL, Wangzhou A, Shiers S et al (2022) Sex differences in Nociceptor Translatomes Contribute to Divergent Prostaglandin Signaling in male and female mice. Biol Psychiatry 91(1):129–140. https://doi.org/10.1016/j.biopsych.2020.09.022
doi: 10.1016/j.biopsych.2020.09.022
pubmed: 33309016
Shen BQ, Sankaranarayanan I, Price TJ, Tavares-Ferreira D (2023) Sex-differences in prostaglandin signaling: a semi-systematic review and characterization of PTGDS expression in human sensory neurons. Sci Rep 13(1):4670. https://doi.org/10.1038/s41598-023-31603-x
doi: 10.1038/s41598-023-31603-x
pubmed: 36949072
pmcid: 10033690
Reichling DB, Green PG, Levine JD (2013) The fundamental unit of pain is the cell. Pain 154 Suppl 1S2–9. https://doi.org/10.1016/j.pain.2013.05.037
Belugin S, Diogenes AR, Patil MJ, Ginsburg E, Henry MA, Akopian AN (2013) Mechanisms of transient signaling via short and long prolactin receptor isoforms in female and male sensory neurons. J Biol Chem 288(48):34943–34955. https://doi.org/10.1074/jbc.M113.486571
doi: 10.1074/jbc.M113.486571
pubmed: 24142695
pmcid: 3843105
Ikegami D, Navratilova E, Yue X, Moutal A, Kopruszinski CM, Khanna R et al (2022) A prolactin-dependent sexually dimorphic mechanism of migraine chronification. Cephalalgia 42(3):197–208. https://doi.org/10.1177/03331024211039813
doi: 10.1177/03331024211039813
pubmed: 34510920
Kopruszinski CM, Porreca F, Chichorro JG (2022) Editorial: chronic orofacial pain. Front Pain Res (Lausanne) 3:1086256. https://doi.org/10.3389/fpain.2022.1086256
doi: 10.3389/fpain.2022.1086256
pubmed: 36688086
Kopruszinski CM, Watanabe M, Martinez AL, de Souza LHM, Dodick DW, Moutal A et al (2023) Kappa opioid receptor agonists produce sexually dimorphic and prolactin-dependent hyperalgesic priming. Pain 164(6):e263–e73. https://doi.org/10.1097/j.pain.0000000000002835
doi: 10.1097/j.pain.0000000000002835
pubmed: 36625833
Gadd SL, Clevenger CV (2006) Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol Endocrinol 20(11):2734–2746. https://doi.org/10.1210/me.2006-0114
doi: 10.1210/me.2006-0114
pubmed: 16840534
Qazi AM, Tsai-Morris CH, Dufau ML (2006) Ligand-independent homo- and heterodimerization of human prolactin receptor variants: inhibitory action of the short forms by heterodimerization. Mol Endocrinol 20(8):1912–1923. https://doi.org/10.1210/me.2005-0291
doi: 10.1210/me.2005-0291
pubmed: 16556730
Xie YL, Hassan SA, Qazi AM, Tsai-Morris CH, Dufau ML (2006) Intramolecular disulfide bonds of the prolactin receptor short form are required for its inhibitory action on the function of the long form of the receptor. Mol Cell Biol 29(10):2546–2555. https://doi.org/10.1128/MCB.01716-08
doi: 10.1128/MCB.01716-08
Yang L, Xu M, Bhuiyan SA, Li J, Zhao J, Cohrs RJ et al (2022) Human and mouse trigeminal ganglia cell atlas implicates multiple cell types in migraine. Neuron 110(11):1806–1821. https://doi.org/10.1016/j.neuron.2022.03.003
doi: 10.1016/j.neuron.2022.03.003
pubmed: 35349784
pmcid: 9338779
Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33(1):48–56. https://doi.org/10.1002/ana.410330109
doi: 10.1002/ana.410330109
pubmed: 8388188
Christensen CE, Younis S, Deen M, Khan S, Ghanizada H, Ashina M (2018) Migraine induction with calcitonin gene-related peptide in patients from erenumab trials. J Headache Pain 19(1):105. https://doi.org/10.1186/s10194-018-0927-2
doi: 10.1186/s10194-018-0927-2
pubmed: 30409109
pmcid: 6755614
Ubrogepant (2019) New drug application (NDA); Center for Drug Evaluation and Research (CDER); 211765 – Orig1s000 – Clinical Review(s), https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211765Orig1s000MedR.pdf (Accessed 3 January 2024)
Rimegepant JL (2020) New drug application (NDA); Center for Drug Evaluation and Research (CDER); 212728 – Orig1s000 – Clinical Review(s), https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212728Orig1s000MedR.pdf (Accessed 4 January 2024)
R. K (2023) New drug application (NDA); Center for Drug Evaluation and Research (CDER); 216386 – Orig1s000 – Clinical Review(s), https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216386Orig1s000MedR.pdf (accessed January 4 2024)
Bolay H, Berman NE, Akcali D (2011) Sex-related differences in animal models of migraine headache. Headache 51(6):891–904. https://doi.org/10.1111/j.1526-4610.2011.01903.x
doi: 10.1111/j.1526-4610.2011.01903.x
pubmed: 21631475
Maciuba S, Bowden GD, Stratton HJ, Wisniewski K, Schteingart CD, Almagro JC et al (2023) Discovery and characterization of prolactin neutralizing monoclonal antibodies for the treatment of female-prevalent pain disorders. MAbs 15(1):2254676. https://doi.org/10.1080/19420862.2023.2254676
doi: 10.1080/19420862.2023.2254676
pubmed: 37698877
pmcid: 10498814